Wellfort

What Wellfort does

Wellfort Co., Ltd. (株式会社ウェルフォート) is a Tokyo-based private health-tech company founded in September 2022, operating a preventive-medicine platform that combines at-home genetic, blood, and cancer-risk testing with AI-driven disease prediction/prevention reports and physician-led online consultations. The company's flagship offering, Welltect, is an annual subscription service structured in three tiers — Premium/Standard for executives aged 50+, Light for ages 30–40, and Trial for first-time users — with pricing ranging from ¥79,200 to ¥297,000 per year, plus standalone AI Disease Prediction (¥55,000) and AI Disease Prevention (¥7,700) reports, genetic testing kits (¥32,780), ALA_PDS urine-based cancer risk tests, and proprietary supplements (MUSE2, CENZ, Autophagy Drink).

The technology stack integrates licensed AI components from Genoplan (genetic variant analysis across 7M+ variants and 502 items), SBI Pharma (patented ALA-based urine cancer detection), and a University of Tokyo Matsuo Laboratory-certified venture company for AI prevention advice, all anchored on a data corpus of approximately 4.6 million medical records from health insurance associations and a broader 10-million-person ecosystem. The go-to-market is dual-track: direct-to-consumer e-commerce via shop.wellfort.co.jp for individuals, supplemented by enterprise field sales targeting corporate 健康経営 (health-management) programs with tiered plans differentiated by employee level and supported by free online consultation booking.

The business is supported by an ecosystem of 700+ affiliated medical institutions and 800+ cancer screening facilities (including National Cancer Center Central Hospital and Cancer Research Institute Ariake Hospital), affiliated beauty/fitness studios (Anti-aging Salon AGEM, LIIL), and a Wellfort Points Mall reward program. Marketing leverages Tokyo Metro mass-transit advertising, athlete sponsorships (Yoshinari Katsu), physician endorsement (Dr. Morita), and academic credibility through an Ehime University joint research agreement (April 2023). Services are explicitly restricted to Japan-based customers, and as of late 2024 the company remained early-stage with no disclosed revenue, headcount, or external funding rounds.

Name

Wellfort

Legal name

株式会社ウェルフォート

Website

https://wellfort.co.jp

Company type

Private

Founded year

2022

Operating status

Operating

Short description

Wellfort is a Tokyo-based preventive-medicine startup offering the Welltect subscription platform — combining at-home genetic, blood, and cancer-risk testing with AI disease prediction, prevention advice, and physician consultations — for Japanese consumers and corporate 健康経営 programs.

Ownership category

akta.pro rank

Product category

Preventive Healthcare Services

NAICS

Ambulatory Health Care Services (621), Medical and Diagnostic Laboratories (6215), Services for the Elderly and Persons with Disabilities (624120)

SIC

Services-Health Services (8000), Services-Home Health Care Services (8082), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Connected Therapeutics & Smart Drug Delivery Monitoring (HLACAFAL)

akta.pro secondary industries

Remote Adherence Monitoring & Smart Dispenser Services (HSABALAI), Genomics & Molecular Diagnostics (Trial Support) (HLAGAEAD)

Keywords

• Preventive healthcare
• At-home health monitoring
• Genetic testing services
• AI disease prediction
• Cancer risk screening

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Marketing or Sales, Technology or R&D, Operations, Supply Chain

Revenue model

1. Welltect Subscription Packages: Annual subscription health monitoring packages (ウェルテクト スタンダード, ライト, AI versions, トライアル) with recurring automatic deliveries of test kits and health consultations. Includes first-year and renewal pricing with discounts for returning customers. Revenue is recurring on an annual subscription basis with 3-4x health checks per year.
2. Individual Diagnostic Tests: One-time sale of individual test kits: AI disease prediction reports (¥55,000), AI disease prevention reports (¥7,700), gene testing kits (¥32,780), ALA_PDS cancer risk tests (¥20,900-¥85,800), and MUSE2 supplement (¥7,990). ALA_PDS tests available with or without cancer screening cost guarantee.
3. Supplements and Wellness Products: Sale of proprietary supplement products including MUSE2 (¥7,990), CENZ tablets (¥16,200), and Autophagy Drink (¥25,920). These are one-time purchase items sold through the e-commerce platform.
4. Cancer Screening Cost Guarantee (Insurance): The ALA_PDS cancer risk test with guarantee (保障あり) provides up to ¥200,000/year coverage for cancer screening costs when high-risk results are obtained. This acts as a risk-backstop revenue model with higher per-test pricing.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Core offering

Wellfort operates the Welltect preventive healthcare platform, an at-home health monitoring service that combines genetic testing (Genoplan), blood testing, AI-powered disease prediction/analysis (trained on ~4.6M medical records) and disease prevention programs, ALA_PDS urine-based cancer risk screening, and physician consultations. The company sells subscription plans (PREMIUM for executives, STANDARD for managers, WELLNESS/LIGHT/TRIAL for individuals) and direct-to-consumer supplements (MUSE2, Autophagy Drink, CENZ Tablet) supported by an ecosystem of partner clinics, gyms, and salons.

Product overview

Wellfort operates a platform-based health monitoring ecosystem centered on Welltect, a comprehensive at-home health monitoring service. The core Welltect platform combines four testing modalities (genetic testing via Genoplan, cancer risk screening via ALA_PDS urine test, blood testing, and AI-powered disease prediction/prevention) with online physician consultations. This is complemented by supplementary products including dietary supplements (MUSE2, Autophagy Drink, CENZ), a points mall reward system, and a network of 700+ affiliated medical institutions and gyms. The architecture follows a platform-plus-modules model where Welltect serves as the core service with various bundled or standalone testing, AI analysis, and consultation options across different price tiers (Trial, Light, Standard) for both corporate and individual customers.

Differentiator

Problem solved

Functional benefit

Brands

• Welltect（ウェルテクト）: 自宅完結型の健康モニタリングサービス。遺伝子検査、血液検査、がんリスク検査、AI疾病予測・予防アドバイス、医師オンライン健康相談を提供。
• Wellfort未病プラットフォーム
• ウェルフォートストア

Products and services

• Welltect At-home preventive health monitoring service for corporate and individual customers; combines genetic testing, blood testing, AI disease prediction/analysis, ALA_PDS cancer risk screening, and physician consultations.
• Genoplan Genetic Testing At-home genetic testing kit using microarray analysis to assess hereditary and lifestyle disease risk for individual consumers and corporate plan members.
• AI Disease Prediction AI-driven disease risk prediction report produced from user health/genetic data and the company's medical-records-trained model; available to Welltect subscribers.
• AI Disease Prevention AI-driven preventive intervention program complementing AI Disease Prediction, providing tailored prevention recommendations for Welltect subscribers.
• ALA_PDS Cancer Risk Test Non-invasive urine-based cancer risk screening test sold as part of Welltect and accessible to individual subscribers.
• Welltect Premium Plan Top-tier corporate subscription plan of the Welltect platform designed for executive-level preventive health management.
• Welltect Standard Plan Mid-tier corporate subscription plan of the Welltect platform designed for manager-level preventive health management.
• Welltect Wellness Plan Direct-to-consumer subscription plan of the Welltect platform providing individual preventive health monitoring.
• Welltect Light Plan Lower-priced direct-to-consumer subscription tier of the Welltect platform.
• Welltect Trial Introductory / trial subscription offering allowing new individual users to experience the Welltect preventive health platform.
• MUSE2 Supplement Branded dietary supplement sold to consumers via the Wellfort e-commerce shop.
• Autophagy Drink Branded consumer health drink focused on autophagy-related benefits, sold via Wellfort's e-commerce shop.
• CENZ Tablet Branded tablet supplement produced using the company's proprietary CENZ magma processing technology, sold via the Wellfort e-commerce shop.
• Wellfort Points Mall Loyalty and rewards marketplace for Wellfort customers to redeem points earned via subscriptions and purchases.
• Anti-aging Salon AGEM Anti-aging salon offering in-person services as part of the company's preventive-health ecosystem.
• LIIL Beauty Salon Beauty salon partner within the Wellfort preventive-health ecosystem, providing in-person services to customers.

Quantifiable outcome

• Stage I cancer 5-year survival rate exceeds 80% across multiple cancer types, making early detection critical for survival
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered core, major and minor.

• Ehime University (愛媛大学) - Food Health Function Research CentercoreStrategic or Co-development Partner · 1 April 2023Wellfort entered a joint research agreement with Ehime University's College of Agriculture Food Health Function Research Center (led by Associate Director Nishikou) from April 1, 2023. The research aims to improve QOL and extend healthy life expectancy for elderly populations by exploring the effectiveness of black ginger (黒生姜) derived ingredients in addressing dementia, sarcopenia/frailty, osteoporosis, and anti-inflammatory conditions. This research addresses Japan's aging society challenge.
• University of Tokyo Matsuo Laboratory (東京大学松尾研究室)coreTechnology or IntegrationWellfort's AI Disease Prevention service was developed in partnership with a venture company certified by the University of Tokyo's Matsuo Laboratory. The AI reads health checkup results, genetic test results, and questionnaire responses to generate personalized disease prevention reports covering diet, exercise, and sleep recommendations.
• Genoplan Inc. (ジェノプラン)coreTechnology or IntegrationGenoplan provides AI-powered genetic testing technology using microarray chips that analyze 7 million+ genetic variants per person from a single saliva sample. Wellfort resells the Genoplan test kit as part of its Welltect platform, covering 502 genetic items across cancer, general diseases, physical traits, and ancestry.
• SBI Pharma (SBIファーマ)coreTechnology or IntegrationSBI Pharma's patented urine-based cancer risk detection technology (ALA_PDS) is used in Wellfort's cancer risk screening test. The technology uses aminolevulinic acid detection to assess cancer risk from home-collected urine samples, complementing the company's genomic and blood testing services.
• DEMECALcoreTechnology or IntegrationDEMECAL provides at-home blood testing kits used in Welltect's blood monitoring service. Users collect blood samples via finger prick at home and mail the kit to the laboratory for analysis, enabling high-frequency health monitoring without clinic visits.
• National Cancer Center Central Hospital Screening Center (国立研究開発法人国立がん研究センター中央病院 検診センター)majorStrategic or Co-development PartnerOne of Wellfort's 700+ affiliated cancer screening institutions. When Welltect users receive high-risk cancer screening results, they are referred to this premier national cancer hospital for confirmatory examinations.
• Cancer Research Institute Ariake Hospital Screening Center (公益財団法人がん研究会 有明病院)majorStrategic or Co-development PartnerWellfort's 700+ affiliated cancer screening hospital network includes the Cancer Research Institute's Ariake Hospital, a leading cancer treatment and research institution in Japan. Provides confirmatory diagnosis and treatment referrals for Welltect users.
• Anti-aging Salon AGEM (アンチエイジング salon AGEM)minorStrategic or Co-development PartnerAGEM is Wellfort's affiliated/owned anti-aging salon offering personal training, esthetics, Indiba therapy, and hydrogen inhalation services. Located in Roppongi, Tokyo. The salon features as part of Wellfort's wellness ecosystem, providing physical wellness services to Welltect users. Wellfort recruits trainers and estheticians as employees.
• LIIL (Anti-aging Salon)minorStrategic or Co-development PartnerLIIL is Wellfort's affiliated high-end beauty salon located in Azabuaban, Tokyo, offering body and facial esthetics, Indiba, high-intensity body sculpting, hair removal, and anti-aging treatments. Part of the Wellfort wellness service ecosystem.
• Noah (uranoseisuto for cancer risk testing)coreTechnology or IntegrationNoah is the cancer risk test kit brand used in Welltect's urine-based cancer screening. The test kit is distributed through Welltect's subscription service alongside the ALA_PDS test.

Scale indicators7 records

Expansion highlights6 records

Broad incumbents

• H.U. Group Holdings (SRL): Major Japanese clinical laboratory and diagnostic services group providing blood and clinical testing nationwide. Comparable to the diagnostic lab backbone (e.g., DEMECAL partnership) supporting Wellfort's at-home blood draws.
• Mitsui & Co. / CureApp: CureApp is a Japanese prescription digital therapeutics company backed by large-cap investors; sits in the broader Japanese digital health/regulatory space overlapping with Wellfort's clinician-supervised wellness monitoring model.

Direct peers

• DeNA (Healthcare / DE Well): Japanese internet/tech major operating health and wellness consumer services including health management apps and genetic testing offerings. Competes with Wellfort for Japanese consumer health subscriptions and corporate wellness spend.
• 23andMe: Direct-to-consumer genetic testing pioneer offering health-risk and ancestry reports — closest analog for the Genoplan-based 502-item, 7-million-variant genetic kit and AI disease prediction features of the Welltect platform.
• Color Health: US preventive health company providing genetic testing and cancer screening (including employer-sponsored programs). Matches Wellfort's premium-positioned, AI-augmented cancer-risk screening integrated with physician consultations and employer health benefits.
• Prenetics (New): Hong Kong-listed preventive health company offering Circle DNA genetic tests, ColoClear cancer screening, and at-home health monitoring. Directly comparable to Welltect's combination of genetic + cancer screening + AI-driven health insights aimed at high-end consumers in Asia.
• Helix: US-based next-generation genetic testing platform that combines microarray analysis, disease risk reporting, and health-system partnerships — comparable architecture to Wellfort's Genoplan-powered genetic testing with AI analytics and clinical referral network.

Emerging players

• Human Longevity Inc. US premium preventive health practice combining whole-genome sequencing, advanced imaging, and AI-driven longevity insights for high-net-worth individuals — analogous positioning to Wellfort's executive Premium tier.
• Natural Holdings (Euglena): Japanese health/wellness company selling microalgae-based supplements and adjacent health products through consumer channels. Overlaps with Wellfort's MUSE2, CENZ, and Autophagy Drink supplement lines and wellness positioning.

Others

• SBI Holdings: Parent group of SBI Pharma, which licenses the patented urine-based ALA cancer-detection technology to Wellfort. Relevant industry connection as the upstream licensor rather than direct competitive peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/wellfort928
• YouTubeyoutube.com/channel/UC_xJ5s9D-RiT_7zT9BZl3Yw
• Instagraminstagram.com/wellfort_official

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Wellfort